Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
At the core of Quetzal's mission is a belief that cutting-edge science, guided by proven leadership, can redefine what's possible in treatment for conditions like Acute Promyelocytic Leukemia ('APL') and invasive infections. The company has formed around a multi-asset pipeline, initially including: QTX-2101: A novel oral arsenic trioxide therapy for the treatment of APL expected to enter Phase III clinical trials by late 2025, supported by encouraging comparative pharmacokinetic data from a Phase 1b trial sponsored by Syros Pharmaceuticals, Inc.
QTX-2102, a next-generation antifungal and antiparasitic therapy in preclinical development, designed to improve efficacy while minimizing toxicity.
Built on Leadership Excellence
Quetzal is led by an executive team with deep expertise in drug development, clinical strategy, and operational execution. 'Our team was brought together by a shared conviction: that patients with rare diseases deserve the same urgency and innovation as those with more common conditions,' said Usman Ahmed, CEO. 'Quetzal Therapeutics is built to deliver on that promise with the right science, the right strategy, and the right people.'
Usman Ahmed, CEO & Chairman – A proven leader with over two decades of leadership in pharmaceuticals and start-up innovation. During his tenure at Nexus Pharmaceuticals, Usman led the execution of complex transactions, spearheaded operational improvements, and championed cost efficiencies in the highly specialized and challenging field of specialty and generic injectables.
Dr. Sridhar Desikan, Co-Founder & Chief Scientific Officer – An industry veteran with 28 years of experience in NCE and generics development. Sridhar began his career at Novartis Pharmaceuticals and subsequently worked at DuPont Pharma, Bristol-Myers Squibb, Dr. Reddy's, and most recently at Nexus Pharmaceuticals as Chief Scientific Officer. Sridhar holds a Ph.D. in Chemical Engineering and has accreditations from Harvard Medical School's HMX Pro program.
Sara Mathews, Vice President Program Leadership – With nearly 15 years of experience in the biotech industry, Sara is a seasoned asset leader with a proven track record of bringing cross-functional teams together and leading novel oncology therapeutics through global clinical programs from IND filing through late-stage development, filing preparation, and commercial launch planning.
Christina Liwski, General Counsel & CHRO – With over a decade of diverse and sophisticated legal experience, Christina brings deep legal acumen to the team. Christina's experience spans multiple practice areas, including transactions and litigation. She most recently served as Assistant General Counsel at Nexus Pharmaceuticals, LLC and is admitted to practice in Illinois, Massachusetts, and the United States District Court for the District of Massachusetts.
Guided by an Accomplished Board of Directors
The company's Board of Directors features industry leaders with a track record of building, funding, and guiding successful companies:
Aman Ahmed – With nearly a decade of experience in the pharmaceutical industry, Aman brings deep expertise in sales operations, DEA and FDA regulatory compliance, international sales, and therapeutic portfolio management.
Dr. Jonathan Cheng – Dr. Jonathan Cheng is a physician-scientist and oncology drug development expert with a distinguished career across both industry and academia. As Chief Medical Officer at Systimmune, he leads the clinical development of a diverse pipeline of novel therapeutics, including innovative antibody-drug conjugates (ADCs) and the company's first-in-class EGFR-HER3 bispecific ADC currently in Phase 3 trials.
Todd Chermak, R.Ph., Ph.D – Todd Chermak is a life sciences executive with 30 years of experience spanning the biopharmaceutical, diagnostics, and nutrition industries. He currently serves as Senior Vice President and Global Business Head of Immunology and Proteomics at CellCarta.
Mike Warmuth – Mike Warmuth is currently working on various Boards: for profit, academic, and not-for-profit. From 2018 to 2023 Mr. Warmuth worked for EW Healthcare as an Operating Partner in their New York office. Prior to EW, Mr. Warmuth spent 30 years at Abbott in various senior executive capacities, where he led multiple divisions and business units.
Strategic Talent Acquisition Partnership
Quetzal Therapeutics proudly acknowledges the role of Heidrick & Struggles, a premier global leadership advisory firm, in identifying and recruiting Dr. Jonathan Cheng to the company's Board of Directors. Their expertise and commitment to excellence were instrumental in securing a highly respected thought leader whose insight will help shape Quetzal's long-term scientific and clinical strategy.
For more information, please visit: www.quetzaltx.com
Media Contact:
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
10 hours ago
- Fast Company
Snowflake is betting big on agentic AI to transform enterprise data work
While much of the buzz about AI today revolves around flashy copilots and productivity hacks, the reality for most data scientists and data engineering teams remains far less glamorous. Even in 2025, they still spend much of their time on the most tedious part of the job: cleaning and preparing data, i.e., dealing with missing values, duplicates, and inconsistencies. But Snowflake CEO Sridhar Ramaswamy wants to change that—not by replacing the people doing the work, but by eliminating the friction that slows them down, such as the endless cycles of reactive reporting. His bold bet is on agentic AI: autonomous model instances that can ingest data, reason over it, and make real-time decisions with minimal human engineering input. 'Until now, AI tools have been excellent at one-step tasks: You ask a question, you get an answer; you ask for code, you get a snippet. They are powerful assistants, but they require constant direction,' Ramaswamy tells Fast Company. 'In the enterprise [space], agentic AI means goal-directed autonomy.' From Data Silos to Conversational Insight reported its first billion-dollar quarter in May 2025, marking a 26% year-over-year increase.
Yahoo
a day ago
- Yahoo
Getac and Eclypsium Partner to Deliver Secure, Rugged Solutions for Federal and Public Safety Agencies
IRVINE, Calif., July 29, 2025 /PRNewswire/ -- Getac Technology Corporation ("Getac"), a leading manufacturer of rugged computing solutions, today announced a strategic partnership with Eclypsium, the infrastructure supply chain security company protecting critical hardware, firmware, and software infrastructure. The collaboration aims to deliver integrated, secure and compliant technology solutions tailored for the U.S. Department of Defense (DoD), federal agencies and public safety organizations. The collaboration addresses critical security challenges facing government organizations, including firmware-level threats, enhancing asset visibility and ensuring compliance with federal cybersecurity mandates. Eclypsium's Supply Chain Security Platform, listed on the CDM Approved Product List (APL), brings proven, policy-aligned protection to Getac's trusted rugged computing hardware. "Getac identified Eclypsium as the de facto standard in firmware and supply chain security," said Charlie Gibbs, Director of Product Solutions at Getac. "Federal agencies and public safety organizations require rugged solutions that are not only operationally reliable but also secure by design. This partnership gives our customers both." Combining Getac's rugged, mission-critical devices with Eclypsium's industry-leading firmware and digital supply chain security platform, the partnership provides a robust solution to address the complex compliance and cybersecurity needs of today's most demanding government environments. "By leveraging Getac's leadership in ruggedized computing, we're able to bring our security capabilities to frontline environments where resilience and protection are mission-critical," said Scott Lupfer, Vice President, Global Alliances and Channels at Eclypsium. While the initial focus of the partnership is on rugged computing devices, both companies are actively exploring opportunities to extend security capabilities into Getac's video solutions portfolio – broadening the impact of this collaboration in the near future. To learn more about the products and solutions enabled by this partnership, please visit ### About Eclypsium Eclypsium's cloud-based and on-premises platform provides digital supply chain security for critical software, firmware and hardware in enterprise infrastructure. Eclypsium helps enterprises and government agencies mitigate risks to their infrastructure from complex technology supply chains. The Eclypsium platform is the only supply chain security solution for enterprise hardware and firmware listed on the CDM APL, recognized as an instrumental Asset Management and Network Security Management solution. For more information, visit About Getac Getac Technology Corporation is a global leader in AI-capable rugged mobile technology and intelligent video solutions, including laptops, tablets, software, body-worn cameras, in-car video systems, digital evidence management and enterprise video analytics solutions. Getac's solutions and services are designed to enable extraordinary experiences for frontline workers in challenging environments. Today, Getac serves customers in over 100 countries spanning defense, public safety, ambulance, fire & rescue, utilities, automotive, natural resources, manufacturing, transport, and logistics. Getac was recently recognized as one of Newsweek's "World's Most Trustworthy Companies" for 2024. For more information, visit: Participate in the Getac Industry blog or follow the company on LinkedIn and YouTube. Getac and Getac logo are trademarks of Getac Holdings Corporation or its affiliates. Other brands or trademarks are the property of their respective owners. ©2025 Getac Technology Corporation. For more information, contact: Kendra Dorr (on behalf of Getac)The Hoffman Agencykdorr@ Eclypsium Media Contact pr@ View original content to download multimedia: SOURCE Getac Sign in to access your portfolio
Business Upturn
16-07-2025
- Business Upturn
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital. Founded to address urgent unmet needs in rare and life-threatening diseases, Quetzal brings together a team of seasoned executives, scientific pioneers, and biotech & pharmaceutical veterans committed to delivering transformative therapies to patients around the world. At the core of Quetzal's mission is a belief that cutting-edge science, guided by proven leadership, can redefine what's possible in treatment for conditions like Acute Promyelocytic Leukemia ('APL') and invasive infections. The company has formed around a multi-asset pipeline, initially including: QTX-2101: A novel oral arsenic trioxide therapy for the treatment of APL expected to enter Phase III clinical trials by late 2025, supported by encouraging comparative pharmacokinetic data from a Phase 1b trial sponsored by Syros Pharmaceuticals, Inc. QTX-2102, a next-generation antifungal and antiparasitic therapy in preclinical development, designed to improve efficacy while minimizing toxicity. Built on Leadership Excellence Quetzal is led by an executive team with deep expertise in drug development, clinical strategy, and operational execution. 'Our team was brought together by a shared conviction: that patients with rare diseases deserve the same urgency and innovation as those with more common conditions,' said Usman Ahmed, CEO. 'Quetzal Therapeutics is built to deliver on that promise with the right science, the right strategy, and the right people.' Usman Ahmed, CEO & Chairman – A proven leader with over two decades of leadership in pharmaceuticals and start-up innovation. During his tenure at Nexus Pharmaceuticals, Usman led the execution of complex transactions, spearheaded operational improvements, and championed cost efficiencies in the highly specialized and challenging field of specialty and generic injectables. Dr. Sridhar Desikan, Co-Founder & Chief Scientific Officer – An industry veteran with 28 years of experience in NCE and generics development. Sridhar began his career at Novartis Pharmaceuticals and subsequently worked at DuPont Pharma, Bristol-Myers Squibb, Dr. Reddy's, and most recently at Nexus Pharmaceuticals as Chief Scientific Officer. Sridhar holds a Ph.D. in Chemical Engineering and has accreditations from Harvard Medical School's HMX Pro program. Sara Mathews, Vice President Program Leadership – With nearly 15 years of experience in the biotech industry, Sara is a seasoned asset leader with a proven track record of bringing cross-functional teams together and leading novel oncology therapeutics through global clinical programs from IND filing through late-stage development, filing preparation, and commercial launch planning. Christina Liwski, General Counsel & CHRO – With over a decade of diverse and sophisticated legal experience, Christina brings deep legal acumen to the team. Christina's experience spans multiple practice areas, including transactions and litigation. She most recently served as Assistant General Counsel at Nexus Pharmaceuticals, LLC and is admitted to practice in Illinois, Massachusetts, and the United States District Court for the District of Massachusetts. Guided by an Accomplished Board of Directors The company's Board of Directors features industry leaders with a track record of building, funding, and guiding successful companies: Aman Ahmed – With nearly a decade of experience in the pharmaceutical industry, Aman brings deep expertise in sales operations, DEA and FDA regulatory compliance, international sales, and therapeutic portfolio management. Dr. Jonathan Cheng – Dr. Jonathan Cheng is a physician-scientist and oncology drug development expert with a distinguished career across both industry and academia. As Chief Medical Officer at Systimmune, he leads the clinical development of a diverse pipeline of novel therapeutics, including innovative antibody-drug conjugates (ADCs) and the company's first-in-class EGFR-HER3 bispecific ADC currently in Phase 3 trials. Todd Chermak, Ph.D – Todd Chermak is a life sciences executive with 30 years of experience spanning the biopharmaceutical, diagnostics, and nutrition industries. He currently serves as Senior Vice President and Global Business Head of Immunology and Proteomics at CellCarta. Mike Warmuth – Mike Warmuth is currently working on various Boards: for profit, academic, and not-for-profit. From 2018 to 2023 Mr. Warmuth worked for EW Healthcare as an Operating Partner in their New York office. Prior to EW, Mr. Warmuth spent 30 years at Abbott in various senior executive capacities, where he led multiple divisions and business units. Strategic Talent Acquisition Partnership Quetzal Therapeutics proudly acknowledges the role of Heidrick & Struggles, a premier global leadership advisory firm, in identifying and recruiting Dr. Jonathan Cheng to the company's Board of Directors. Their expertise and commitment to excellence were instrumental in securing a highly respected thought leader whose insight will help shape Quetzal's long-term scientific and clinical strategy. For more information, please visit: Media Contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
